Research Article
Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group
Table 1
Characteristics of 82 patients with available tumor mRNA and of the subset of 27 patients with centrally reviewed MIBG diagnostic scans.
| | Entire cohort () | Subset of patients centrally reviewed () |
| Median age (range) | 11.9 months (0.1–171.7 months) | 33 months (3.8–171.7 months) | Age > 18 months at diagnosis | 35/82 (42.7%) | 22/27 (81%) | Intermediate-risk group : High-risk group | 31 : 51 | 0 : 27 | Adrenal primary tumor | 38/82 (46.3%) | 16/27 (59%) | Stage 4 : Stage 4S : Localized tumors | 39 : 7 : 36 | 15 : 2 : 10 | MYCN-amplified tumor | 15/82 (18.3%) | 14/27 (51.8%) | Unfavorable histology | 29/80 (36.3%) | 24/26 (92.3%) | Elevated baseline urine catecholamines | 20/31 (64.5%)a | 16/27 (59.3%) | MIBG avid tumor at diagnosis | 53/82 (64.6%)b | 19/27 (70.3%) |
|
|
aAvailable only in patients with high-risk disease.
bInstitutional report.
|